Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE0005664809
Tue, 10.05.2022
Evotec SE
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today that the Company has extended and expanded its partnership with Bristol Myers Squibb (NYSE:BMY) in targeted protein degradation, originally signed in 2018.
Aim of the eight-year extension is to develop a broad p [ … ]
Fri, 04.02.2022
Evotec SE
Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target resea [ … ]
Thu, 04.11.2021
Evotec SE
Hamburg, Germany, 3 November 2021 - Evotec SE's (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) management board today decided - with the approval of its supervisory board - on the volume and the issue price of its public offering of American Depositary Shares ("ADSs"). The offering will produce gross proceeds of $ 435, [ … ]
Tue, 03.08.2021
Evotec SE
Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480) announces that the Company has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory ch [ … ]
Mon, 02.08.2021
Evotec SE
Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announces that it confidentially submitted a Registration Statement on Form F-1 ("Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") for a proposed offering and sale in the United States of shares of Evotec repres [ … ]
Fri, 23.04.2021
Evotec SE
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announces that t [ … ]
Tue, 13.10.2020
Evotec SE
Disclosure of an inside information according to Article 17 MARMubadala Investment Company and Novo Holdings A/S invest € 250 million in Evotec SEHamburg, Germany - Evotec SE (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) today announced that it resolved on a capital increase from its authorised capital without pre-emp [ … ]